The company is scaling up manufacturing and commercial activities as it prepares to enter the U.S. market via the Food and Drug Administration’s de novo pathway.

Tasso, maker of at-home blood sample collection systems, is launching the next generation of its devices that aim to support patients enrolled in clinical trials and simplify their participation in ...